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Commentary

Elaine Goh,1 Andrea Guerin,2 Joanna Lazier,3
Sharan Goobie,4 Tanya N Nelson,5,6 Ron Agatep,7 Victoria Mok Siu,8
Karen Y Niederhoffer,3 Julie Richer9
Choosing Wisely Canada aims to reduce
patient harm by promoting discussion and
awareness of unnecessary tests, procedures and treatments. Organised by Canadian physicians and the Canadian Medical
Association,1 it is modelled after the
American Choosing Wisely campaign.2
The concept of ‘Choosing Wisely’ is now
an international effort, across more than
15 countries.1
The advances in genome sequencing
technology have allowed for increased
diagnostic
yield
while
unmasking
secondary findings or information of
limited clinical utility.3 These findings
may contribute to further unnecessary
diagnostic testing, lifelong surveillance
for low-risk sequelae and side effects of
preventative treatment in healthy individuals, all of which may have economic
consequences.3 Therefore, recommendations by genetics professionals to improve
health and decrease costs are needed.
The Canadian College of Medical
Geneticists (CCMG) is the national organisation that establishes Canadian professional and ethical standards for medical
genetics services. The CCMG through the
leadership of the Ethics, Education, and
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Public Policy Committee (E2P2), undertook an iterative process to formulate
five items physicians and patients should
question in medical genetics as part of
Choosing Wisely Canada.
The initial statements (Summer 2015)
were generated by a subcommittee of
E2P2. Seven statements with the option
for additions were presented in a pilot
survey at the 2015 CCMG annual
conference. For reference, the five
statements from the American Choosing
Wisely campaign were also provided.4
After feedback, the statements from the
pilot survey were modified or replaced
by new ones and distributed to the
entire CCMG membership (n=318) by
electronic survey (SurveyMonkey, San
Mateo, California, USA) in March 2016
for ranking. Answers were weighted, and
the five top statements were selected.
The results of statement ranking by
53/318 (17%) members responding to
the electronic survey can be found in
table 1. The top five statements chosen
for literature review are bolded.
E2P2 reviewed the literature, generated a rationale for each statement and
presented these orally during the 2016
CCMG annual meeting for comment.
Following revision, statements and their
rationale were posted for comment
online for 1 month with one reminder
email sent to the membership. E2P2
reviewed comments and edited statements prior to submission to the 151
Choosing Wisely Society Leads from
other specialties (Fall 2016). Comments
were received and addressed, including
a change from ‘non-invasive prenatal
testing’
(NIPT)
to
‘non-invasive
prenatal detection of fetal aneuploidies
by cell-free DNA’ and keeping the term
‘children’ rather than ‘minors’ despite
objection, to be consistent with other
society statements.5 6
The final statements as below were
submitted to the Choosing Wisely Canada
organisation on 1 January 2017:
Goh E, et al. J Med Genet February 2018 Vol 55 No 2

Don’t use non-invasive prenatal
detection of fetal aneuploidies by
cell-free DNA as a diagnostic test

Non-invasive prenatal detection of fetal
aneuploidies by cell-free DNA, also
called non-invasive prenatal testing and
non-invasive prenatal screening, is a
method of non-invasive fetal DNA testing
done through a maternal blood sample.
NIPT testing for common aneuploidies,
microdeletions and sex chromosome
disorders7 is clinically available to patients
in Canada. NIPT is a highly sensitive and
specific screening test but is not diagnostic.8 Even in high-risk populations,
there can be false-positive NIPT results.
Genetic counselling, along with confirmatory testing via amniocentesis or chorionic
villus sampling, should be done prior to
using the result to impact management of
a pregnancy.

Don’t make medical decisions
based on results of direct to
consumer genetic testing without
a clear understanding of the
limitations and validity of the test

Three types of potentially medically relevant direct to consumer genetic
testing (DTC-GT) are available: (1) assessment of risk for common multifactorial
diseases (eg, diabetes); (2) targeted mutation analysis for single gene disorders; and
(3) sequencing. Some DTC-GT companies
state that they do not guarantee the accuracy or reliability of their tests. Many of
the significant genetic risk and protective
factors for multifactorial conditions have
not been identified. This leads to greatly
divergent risk interpretations between
companies, even when performed on the
same individual.9 For targeted mutation
analysis and sequencing, the specific test
may not include all clinically relevant
genes or mutations, resulting in false reassurance.10 Genetic changes that are only
weakly associated with disease may be
reported, leading to anxiety or inappropriate additional testing. When making
medical decisions based on results of
genetic testing, the test should meet the
recommendations made by the CCMG
in 2012.11 Not all DTC-GT meet these
recommendations.

Don’t order a chromosome
analysis by doing a karyotype
for individuals with intellectual
disability/developmental delay of
unknown aetiology

Microarray is the first-line test for individuals with intellectual disability/
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Rating average following the membership survey (n=53)

Statements

Response count Rating average*

Don't order whole exome sequencing prior to genetic counselling.

42

3.60

Don't make medical decisions based on results of direct to consumer genetic testing (DTC-GT) without having a clear
understanding of the limitation and validity of the specific test used.

39

3.54

Don't order carrier testing in paediatric patients if these results will not impact their health care management in the
paediatric period.

41

3.46

Don't use NIPT as a diagnostic test.

26

3.27

Don't do a karyotype in a patient presenting for developmental delay (as microarray is now the standard of care).

41

3.20

Don't order an amniocentesis for an increased maternal AFP if the 18–20 week ultrasound was normal with adequate visualisation.

22

2.77

Don't do a karyotype if a microarray has already been ordered/performed.

19

2.74

Don't order genetic testing for HFE-related hemochromatosis in patients who have an isolated mild elevation of ferritin.

28

2.61

*Weighted based on whether statement was chosen as first, second, third, fourth or fifth choice.
AFP, alpha feto protein; NIPT, non-invasive prenatal testing.
Bolded statements selected for literature review.

developmental delay without a recognisable syndrome.12 Indeed, a microarray has
a much higher detection rate (15%–20%)
compared with a karyotype (3%–4%)
in individuals presenting for this clinical indication.13 A karyotype remains
important in limited clinical situations
where a specific numerical or structural
chromosomal syndrome, such as Down
syndrome, is suspected.

Don’t order whole exome
sequencing (WES) prior to genetic
counselling

WES is a powerful test for individuals
suspected of having an underlying genetic
diagnosis. However, WES increases the
likelihood of unexpected findings, which
may or may not be clinically significant.
Furthermore, due to methodological
limitations, WES may not always be the
correct test to order as WES will not
detect all genetic causes of disease (eg,
it will not detect chromosomal structural differences).14 Both informative
and uninformative results can lead to
complex patient and family psychosocial
repercussions15 and could impair future
insurability. Genetic counselling facilitates informed decision making. Given
complexity of results, WES should only
be ordered after counselling by a qualified healthcare provider.

Don’t order carrier testing in
children

Carrier testing is primarily useful in the
reproductive period to determine the risk
of an individual having a child affected
by the condition for which testing is
being considered.5 Knowing that a child
is a carrier of an X-linked or autosomal
recessive condition usually does not alter
medical care in the paediatric years since
most carriers are unaffected. Thus, in most
Goh E, et al. J Med Genet February 2018 Vol 55 No 2

situations, there is not a medical indication for carrier testing in a child.6 Undertaking carrier testing of a child violates the
right of the child to make his or her own
decision about testing and could impair
future insurability. An exception could be
made for a mature adolescent who may be
able to understand the reproductive implications of carrier testing after appropriate
genetic counselling.
This expert CCMG consensus reflects
Choosing Wisely statements covering a
broad range of genetic issues relevant
to Canadians. As no demographic information was collected from the membership survey, it is not known whether the
responses were representative of both
laboratory geneticists and clinical geneticists, but there were equal opportunities
for both to provide feedback.
It is interesting that only one statement regarding WES is similar to the
American recommendations.4 While the
American version was specific about
recommending informed consent, particularly around secondary findings, the
Canadian version recommends genetic
counselling, which is more generalised
and would encompass informed consent
as part of the counselling process.
Three of the American statements target
specific genetic tests (APO-E, MTHFR
and HFE).4 In Canada, some of these
tests are not routinely offered or covered
by provincial healthcare. It is possible
that the perspective taken in generating
these recommendations in the USA
versus Canada differs based on the target
audience requesting the tests, the healthcare systems or the practice differences
between the two countries. Regardless of
the reason, this report suggests that there
is value in determining country-specific
recommendations. As technology and
knowledge advance, these statements
may need to be revised.

As the goal of the Choosing Wisely
campaign is to reduce patient harm by
generating greater awareness of responsible use of testing and procedures, these
five recommendations represent the start
of a dialogue that will hopefully optimise
utilisation of resources related to medical
genetics.
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